Annual Statements Open main menu

AMPHENOL CORP /DE/ - Quarter Report: 2021 September (Form 10-Q)

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 1-10879

Graphic

AMPHENOL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

22-2785165

(State of Incorporation)

(IRS Employer Identification No.)

358 Hall Avenue

Wallingford, Connecticut 06492

(Address of principal executive offices) (Zip Code)

203-265-8900

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, $0.001 par value

APH

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes   No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes   No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer 

Accelerated Filer 

Non-accelerated Filer 

Smaller Reporting Company 

Emerging Growth Company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No 

As of October 26, 2021, the total number of shares outstanding of the registrant’s Class A Common Stock was 598,027,782.

Table of Contents

Amphenol Corporation

Index to Quarterly Report

on Form 10-Q

    

Page

Part I

Financial Information

Item 1.

Financial Statements (unaudited):

Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020

2

Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2021 and 2020

3

Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2021 and 2020

4

Condensed Consolidated Statements of Cash Flow for the Nine Months Ended September 30, 2021 and 2020

5

Notes to Condensed Consolidated Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

27

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

41

Item 4.

Controls and Procedures

41

Part II

Other Information

Item 1.

Legal Proceedings

42

Item 1A.

Risk Factors

42

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

42

Item 3.

Defaults Upon Senior Securities

43

Item 4.

Mine Safety Disclosures

43

Item 5.

Other Information

43

Item 6.

Exhibits

43

Signature

46

1

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

AMPHENOL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(dollars in millions)

September 30, 

December 31, 

    

2021

    

2020

 

ASSETS

Current Assets:

Cash and cash equivalents

$

1,268.1

$

1,702.0

Short-term investments

 

34.4

 

36.1

Total cash, cash equivalents and short-term investments

 

1,302.5

 

1,738.1

Accounts receivable, less allowance for doubtful accounts of $44.5 and $44.8, respectively

 

2,204.5

 

1,951.6

Inventories

 

1,952.5

 

1,462.2

Prepaid expenses and other current assets

 

392.1

 

338.9

Current assets held for sale

1,068.2

Total current assets

 

6,919.8

 

5,490.8

Property, plant and equipment, less accumulated depreciation of $1,881.3 and $1,738.6, respectively

1,175.4

1,054.6

Goodwill

5,839.4

5,032.1

Other intangible assets, net

 

603.6

 

397.5

Other long-term assets

387.9

352.3

$

14,926.1

$

12,327.3

LIABILITIES & EQUITY

Current Liabilities:

Accounts payable

$

1,300.0

$

1,120.7

Accrued salaries, wages and employee benefits

 

224.9

 

195.4

Accrued income taxes

 

101.2

 

112.6

Accrued dividends

86.7

86.8

Other accrued expenses

 

666.1

 

558.5

Current portion of long-term debt

 

298.7

 

230.3

Current liabilities held for sale

207.4

Total current liabilities

 

2,885.0

 

2,304.3

Long-term debt, less current portion

 

4,950.0

 

3,636.2

Accrued pension and postretirement benefit obligations

 

221.6

 

228.6

Deferred income taxes

452.2

299.1

Other long-term liabilities

 

408.6

 

407.2

Equity:

Common stock

0.6

0.6

Additional paid-in capital

 

2,289.5

 

2,068.1

Retained earnings

 

4,080.6

 

3,705.4

Treasury stock, at cost

(89.3)

(111.1)

Accumulated other comprehensive loss

 

(335.5)

 

(278.1)

Total shareholders’ equity attributable to Amphenol Corporation

 

5,945.9

 

5,384.9

Noncontrolling interests

 

62.8

 

67.0

Total equity

 

6,008.7

 

5,451.9

$

14,926.1

$

12,327.3

See accompanying notes to condensed consolidated financial statements.

2

Table of Contents

AMPHENOL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(dollars and shares in millions, except per share data)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

  

2021

  

2020

   

2021

  

2020

 

Net sales

$

2,818.5

$

2,323.4

$

7,849.5

$

6,172.9

Cost of sales

 

1,928.6

 

1,588.5

 

5,388.9

 

4,274.4

Gross profit

 

889.9

 

734.9

 

2,460.6

 

1,898.5

Acquisition-related expenses

 

 

 

55.4

 

Selling, general and administrative expenses

 

318.7

 

259.1

 

893.0

 

748.4

Operating income

 

571.2

 

475.8

 

1,512.2

 

1,150.1

Interest expense

 

(29.0)

 

(28.0)

 

(86.7)

 

(87.1)

Other income (expense), net

 

 

1.0

 

(0.3)

 

3.4

Income from continuing operations before income taxes

 

542.2

 

448.8

 

1,425.2

 

1,066.4

Provision for income taxes

 

(120.5)

 

(99.3)

 

(302.8)

 

(213.3)

Net income from continuing operations

421.7

349.5

1,122.4

853.1

Less: Net income from continuing operations attributable to noncontrolling interests

 

(2.9)

 

(2.9)

 

(6.9)

 

(6.7)

Net income from continuing operations attributable to Amphenol Corporation

 

418.8

 

346.6

 

1,115.5

 

846.4

Income from discontinued operations attributable to Amphenol Corporation, net of income taxes of ($1.5) and ($1.8) for 2021, respectively

7.7

10.3

Net income attributable to Amphenol Corporation

$

426.5

$

346.6

$

1,125.8

$

846.4

Net income per common share attributable to Amphenol Corporation — Basic:

Continuing operations

$

0.70

$

0.58

$

1.87

$

1.42

Discontinued operations, net of income taxes

0.01

0.02

Net income attributable to Amphenol Corporation — Basic

$

0.71

$

0.58

$

1.88

$

1.42

Weighted average common shares outstanding — Basic

 

597.7

 

597.5

 

597.8

 

595.2

Net income per common share attributable to Amphenol Corporation — Diluted:

Continuing operations

$

0.67

$

0.56

$

1.79

$

1.38

Discontinued operations, net of income taxes

0.01

0.02

Net income attributable to Amphenol Corporation — Diluted

$

0.68

$

0.56

$

1.80

$

1.38

Weighted average common shares outstanding — Diluted

 

625.8

 

616.4

 

624.6

 

612.5

Note: Per share amounts may not add due to rounding.

See accompanying notes to condensed consolidated financial statements.

3

Table of Contents

AMPHENOL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(dollars in millions)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2021

    

2020

    

2021

    

2020

 

Net income from continuing operations

$

421.7

$

349.5

$

1,122.4

$

853.1

Add: Income from discontinued operations attributable to Amphenol Corporation, net of income taxes

7.7

10.3

Net income before allocation to noncontrolling interests

$

429.4

$

349.5

$

1,132.7

$

853.1

Total other comprehensive (loss) income, net of tax:

Foreign currency translation adjustments

 

(39.7)

 

102.9

 

(72.2)

 

28.7

Unrealized (loss) gain on hedging activities

 

(0.5)

 

0.4

 

0.4

 

(0.2)

Pension and postretirement benefit plan adjustment, net of tax of ($1.6) and ($4.9) for 2021, and ($1.7) and ($5.0) for 2020, respectively

 

5.1

 

5.2

 

15.3

 

15.5

Total other comprehensive (loss) income, net of tax

 

(35.1)

 

108.5

 

(56.5)

 

44.0

Total comprehensive income

 

394.3

 

458.0

 

1,076.2

 

897.1

Less: Comprehensive income attributable to noncontrolling interests

 

(3.0)

 

(5.2)

 

(7.8)

 

(8.2)

Comprehensive income attributable to Amphenol Corporation

$

391.3

$

452.8

$

1,068.4

$

888.9

See accompanying notes to condensed consolidated financial statements.

4

Table of Contents

AMPHENOL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)

(dollars in millions)

Nine Months Ended September 30, 

 

    

2021

    

2020

 

Cash from operating activities:

Net income from continuing operations

$

1,122.4

$

853.1

Adjustments to reconcile net income from continuing operations to cash provided by operating activities from continuing operations:

Depreciation and amortization

 

274.5

 

218.0

Stock-based compensation expense

 

60.2

 

51.0

Deferred income tax provision (benefit)

 

24.9

(5.8)

Net change in components of working capital

(414.1)

38.6

Net change in other long-term assets and liabilities

(7.5)

(3.9)

Net cash provided by operating activities from continuing operations

1,060.4

1,151.0

Net cash provided by operating activities from discontinued operations

9.1

Net cash provided by operating activities

 

1,069.5

 

1,151.0

Cash from investing activities:

Capital expenditures

 

(274.2)

 

(204.8)

Proceeds from disposals of property, plant and equipment

 

2.4

 

10.8

Purchases of short-term investments

 

(128.0)

 

(89.3)

Sales and maturities of short-term investments

 

129.3

 

71.1

Acquisitions, net of cash acquired

 

(1,531.0)

 

(50.3)

Other

(8.5)

Net cash used in investing activities from continuing operations

(1,810.0)

(262.5)

Net cash used in investing activities from discontinued operations

(4.7)

Net cash used in investing activities

 

(1,814.7)

 

(262.5)

Cash from financing activities:

Proceeds from issuance of senior notes and other long-term debt

 

749.9

 

942.3

Repayments of senior notes and other long-term debt

 

(616.2)

(402.9)

Borrowings under credit facilities

 

 

1,567.4

Repayments under credit facilities

(1,568.1)

Borrowings (repayments) under commercial paper programs, net

925.0

(385.9)

Payment of costs related to debt financing

 

(6.1)

 

(8.7)

Payment of acquisition-related contingent consideration

 

 

(75.0)

Proceeds from exercise of stock options

 

180.9

256.6

Payment of deferred purchase price related to acquisitions

(4.1)

(16.2)

Distributions to and purchases of noncontrolling interests

(11.3)

(11.5)

Purchase of treasury stock

 

(491.0)

 

(459.2)

Dividend payments

 

(260.0)

 

(223.0)

Transfers to discontinued operations

(28.7)

Net cash provided by (used in) financing activities from continuing operations

438.4

(384.2)

Net cash used in financing activities from discontinued operations

(0.1)

Net cash provided by (used in) financing activities

 

438.3

 

(384.2)

Effect of exchange rate changes on cash and cash equivalents

 

(15.5)

 

25.0

Net (decrease) increase in cash and cash equivalents

 

(322.4)

 

529.3

Cash and cash equivalents balance, beginning of period

 

1,702.0

 

891.2

Cash and cash equivalents balance, end of period

$

1,379.6

$

1,420.5

Less: Cash and cash equivalents included in Current assets held for sale, end of period

 

111.5

 

Cash and cash equivalents balance of continuing operations, end of period

$

1,268.1

$

1,420.5

Cash paid for:

Interest

$

78.8

$

74.5

Income taxes, net

 

305.4

 

262.9

See accompanying notes to condensed consolidated financial statements.

5

Table of Contents

AMPHENOL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(amounts in millions, except share and per share data, unless otherwise noted)

Note 1—Basis of Presentation and Principles of Consolidation

The Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020, the related Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2021 and 2020, and the related Condensed Consolidated Statements of Cash Flow for the nine months ended September 30, 2021 and 2020, include the accounts of Amphenol Corporation and its subsidiaries (“Amphenol,” the “Company,” “we,” “our,” or “us”). All material intercompany balances and transactions have been eliminated in consolidation. The condensed consolidated financial statements included herein are unaudited. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, including normal recurring adjustments considered necessary for a fair presentation of the results, in conformity with accounting principles generally accepted in the United States of America. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements and the related notes should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 Annual Report”).

Stock Split

On January 27, 2021, the Company announced that its Board of Directors approved a two-for-one split of the Company’s Common Stock. The stock split was effected in the form of a stock dividend paid to shareholders of record as of the close of business on February 16, 2021. The additional shares were distributed on March 4, 2021, and the Company’s Common Stock began trading on a split-adjusted basis on March 5, 2021. As a result of the stock split, shareholders received one additional share of Amphenol Common Stock, $0.001 par value, for each share held as of the record date.

All current and prior year data presented in the accompanying Condensed Consolidated Financial Statements and notes thereto in this Form 10-Q, including but not limited to, number of shares and per share information, stock-based compensation data including stock options and restricted shares and related per share data, basic and diluted earnings per share, and dividends per share amounts, have been adjusted to reflect the effect of the stock split. As a result of the stock split, certain prior period amounts have been reclassified to conform to the current period presentation in the Condensed Consolidated Financial Statements and accompanying notes herein. The impact to the Condensed Consolidated Balance Sheets, as well as the rollforward of consolidated changes in equity included in Note 7 herein, was an increase of $0.3 to Common Stock, with an offsetting decrease in Additional paid-in capital, which has been retroactively adjusted for all periods presented.

While the stock split did not change the number of authorized common shares of the Company, in May 2021, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of Common Stock, which amendment was filed and became effective on May 21, 2021. Refer to Note 7 herein for further details related to the increase in the number of shares of Common Stock authorized for issuance as a result of this amendment.

Discontinued Operations

The Company reports an operation’s assets and liabilities separately as “held for sale” when (1) management, having the authority to approve the action, commits to a plan to sell the discontinued operation, the plan of which is unlikely to have any significant changes or to be withdrawn, (2) the completed sale is probable within one year and (3) an active program to locate a buyer has been initiated with the operation actively marketed for sale at a price that is reasonable in relation to its current fair value and for immediate sale in its present condition. In December 2020, the Company signed a definitive agreement to acquire MTS Systems Corporation (Nasdaq: MTSC) (“MTS”) as more fully

6

Table of Contents

discussed in Note 11 herein. On January 19, 2021, the Company entered into a definitive agreement to sell the MTS Test & Simulation (“MTS T&S”) business to Illinois Tool Works Inc. (NYSE: ITW). The Company closed on the acquisition of MTS on April 7, 2021. The Company expects to close on the sale of the MTS T&S business as soon as all required regulatory approvals have been received and other customary closing conditions have been satisfied, which the Company expects to be within the one-year period outlined above. The Company concluded that the MTS T&S business met the “held for sale” criteria upon the closing of the MTS acquisition and, as such, the assets and liabilities are presented as held for sale and classified as current as of September 30, 2021 in the Condensed Consolidated Balance Sheets and accompanying Notes herein. The financial results and cash flows associated with the MTS T&S business are also accounted for as discontinued operations in the accompanying Condensed Consolidated Statements of Income and Statements of Cash Flow, respectively, for all current year periods presented. The comprehensive income associated with discontinued operations is not material and has not been separately presented in the Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2021.

Refer to Note 11 herein for further information related to the acquisition of MTS, along with Note 12 herein for further discussion of the Company’s discontinued operations associated with the MTS T&S business including the Company’s planned divestiture thereof.

Note 2—New Accounting Pronouncements

Recently Adopted Accounting Standards and Final SEC Rules

In December 2019, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplified income tax accounting in various areas. The Company evaluated ASU 2019-12 and adopted the standard on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements.

In May 2020, the Securities and Exchange Commission (the “SEC”) issued a new rule regarding the financial statement requirements for acquisitions and dispositions of a business, which included, among other things, amending (i) certain criteria in the significance tests for acquired or to-be-acquired businesses, (ii) related pro forma financial information requirements, including its form and content, and (iii) related disclosure requirements, including the number of acquiree financial statement periods required to be presented in SEC filings. The final rule was effective for fiscal years beginning after December 31, 2020, with early application permitted. The Company evaluated this SEC final rule, which we adopted on January 1, 2021. To date, the final rule has not had a material impact on our condensed consolidated financial statements. Its impact on any future SEC filings will be dependent on the size of future business combinations and/or divestitures.

Recently Issued Accounting Standards and Final SEC Rules Not Yet Adopted

The United Kingdom’s Financial Conduct Authority (the “FCA”), which regulates the London Interbank Offered Rate (“LIBOR”), announced in July 2017 its intent to phase out the use of LIBOR by the end of 2021. In December 2020, the ICE Benchmark Administration published a consultation on its intention to extend the publication of certain U.S. dollar LIBOR (“USD LIBOR”) rates until June 30, 2023. Subsequently in March 2021, the FCA announced some USD LIBOR tenors (overnight, 1-month, 3-month, 6-month and 12-month) will continue to be published until June 30, 2023. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, identified the Secured Overnight Financing Rate (the “SOFR”) as its preferred benchmark alternative to USD LIBOR. The SOFR represents a measure of the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is calculated based on directly observable U.S. Treasury-backed repurchase transactions. In March 2020, in response to this transition, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) – Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides optional expedients and exceptions for applying accounting principles generally accepted in the United States (“U.S. GAAP”) to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued by reference rate reform, and addresses operational issues likely to arise in modifying contracts to replace discontinued reference rates with new rates. ASU 2020-04 is effective as of March 12, 2020 through December 31, 2022. In January 2021, the FASB also issued ASU 2021-01 Reference Rate Reform (Topic

7

Table of Contents

848): Scope, which permits entities to elect certain optional expedients and exceptions when accounting for derivatives and certain hedging relationships affected by changes in interest rates and the transition. The Company is evaluating the potential impact of the replacement of LIBOR from both a risk management and financial reporting perspective. Our current portfolio of debt and financial instruments tied to LIBOR consists primarily of our Revolving Credit Facility (as defined below), which had no outstanding borrowings as of September 30, 2021. We do not currently believe that this transition will have a material impact on our financial condition, results of operations or cash flows.

In November 2020, the SEC issued a new rule that modernizes and simplifies various aspects and financial disclosure requirements in Regulation S-K, specifically related to Item 301 “Selected Financial Data”Item 302 “Supplementary Financial Information” and Item 303 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (“MD&A”). The intent of this new rule is to (i) eliminate duplicative disclosures, (ii) enhance and promote more principles-based MD&A disclosures with the objective of making them more meaningful for investors, all while (iii) simplifying the compliance requirements and efforts for registrants, by providing them with the flexibility to present management’s perspective on the registrant’s financial condition and results of operations. While most of the changes involve reducing or eliminating previously required information and disclosures, the rule does expand the disclosure requirements surrounding certain aspects of the various items in Regulation S-K discussed above. The final rule was published in the Federal Register on January 11, 2021, became effective thirty days after its publication date, or February 10, 2021, and registrants are required to comply with this final rule in the registrant’s first fiscal year ending on or after the date that is 210 days after the publication date (August 9, 2021). The Company has evaluated this SEC final rule, and we plan to incorporate the requirements and amendments of this SEC rule, in its entirety, as part of our Form 10-K for the year ending December 31, 2021. The application of this new SEC rule is not expected to have a material impact on our future SEC filings.

Note 3—Inventories

Inventories consist of:

September 30, 

December 31, 

    

2021

    

2020

 

Raw materials and supplies

 

$

815.2

 

$

587.4

Work in process

 

535.0

 

410.7

Finished goods

 

602.3

 

464.1

 

$

1,952.5

 

$

1,462.2

8

Table of Contents

Note 4—Debt

The Company’s debt (net of any unamortized discount) consists of the following:

 

September 30, 2021

December 31, 2020

 

Carrying

Approximate

Carrying

Approximate

 

    

Amount

    

Fair Value

    

Amount

    

Fair Value

 

Revolving Credit Facility

$

 

$

 

$

 

$

U.S. Commercial Paper Program

 

924.3

 

924.3

 

 

Euro Commercial Paper Program

 

 

 

 

3.125% Senior Notes due September 2021

 

 

 

227.7

 

231.6

4.00% Senior Notes due February 2022

 

295.0

 

295.8

 

294.9

 

303.6

3.20% Senior Notes due April 2024

 

349.9

 

369.6

 

349.8

 

378.1

2.050% Senior Notes due March 2025

399.5

412.4

399.4

420.7

0.750% Euro Senior Notes due May 2026

577.8

597.5

608.4

633.6

2.000% Euro Senior Notes due October 2028

577.7

649.1

608.4

694.9

4.350% Senior Notes due June 2029

499.6

579.2

499.6

608.4

2.800% Senior Notes due February 2030

899.4

945.6

899.4

987.8

2.200% Senior Notes due September 2031

747.3

742.9

Other debt

 

7.6

 

7.6

 

6.7

 

6.7

Less: unamortized deferred debt issuance costs

 

 

(29.4)

 

 

(27.8)

 

Total debt

 

5,248.7

 

5,524.0

 

3,866.5

 

4,265.4

Less: current portion

 

298.7

299.5

 

230.3

 

234.2

Total long-term debt

$

4,950.0

 

$

5,224.5

 

$

3,636.2

 

$

4,031.2

Revolving Credit Facility

The Company has a $2,500.0 unsecured credit facility (the “Revolving Credit Facility”), which matures January 2024 and gives the Company the ability to borrow, in various currencies, at a spread over LIBOR. The Company may utilize the Revolving Credit Facility for general corporate purposes. At September 30, 2021 and December 31, 2020, there were no outstanding borrowings under the Revolving Credit Facility. The carrying value of any borrowings under the Revolving Credit Facility would approximate their fair value due primarily to their market interest rates and would be classified as Level 2 in the fair value hierarchy (Note 5). Any outstanding borrowings under the Revolving Credit Facility are classified as long-term debt in the accompanying Condensed Consolidated Balance Sheets. The Revolving Credit Facility requires payment of certain annual agency and commitment fees and requires that the Company satisfy certain financial covenants. At September 30, 2021, the Company was in compliance with the financial covenants under the Revolving Credit Facility.

Commercial Paper Programs

The Company has a commercial paper program pursuant to which the Company may issue short-term unsecured commercial paper notes (the “USCP Notes”) in one or more private placements in the United States (the “U.S. Commercial Paper Program”). The maturities of the USCP Notes vary, but may not exceed 397 days from the date of issue. The USCP Notes are sold under customary terms in the commercial paper market and may be issued at par or a discount therefrom, and bear varying interest rates on a fixed or floating basis. The maximum aggregate principal amount outstanding of USCP Notes at any time is $2,500.0. On April 7, 2021, a combination of borrowings under the U.S. Commercial Paper Program and cash and cash equivalents on hand were used to fund the acquisition of MTS. Refer to Note 11 herein for further discussion of the acquisition of MTS. In addition, in the third quarter of 2021, the Company used borrowings under the U.S. Commercial Paper Program to redeem its unsecured 3.125% Senior Notes due September 15, 2021, of which $227.7 aggregate principal amount was outstanding. As of September 30, 2021, the amount of USCP Notes outstanding was $924.3, with a weighted average interest rate of 0.19%.

The Company and one of its wholly owned European subsidiaries (collectively, the “Euro Issuer”) also has a commercial paper program (the “Euro Commercial Paper Program” and, together with the U.S. Commercial Paper Program, the “Commercial Paper Programs”) pursuant to which the Euro Issuer may issue short-term unsecured

9

Table of Contents

commercial paper notes (the “ECP Notes” and, together with the USCP Notes, “Commercial Paper”), which are guaranteed by the Company and are to be issued outside of the United States.  The maturities of the ECP Notes will vary, but may not exceed 183 days from the date of issue.  The ECP Notes are sold under customary terms in the commercial paper market and may be issued at par or a discount therefrom or a premium thereto and bear varying interest rates on a fixed or floating basis. The ECP Notes may be issued in Euros, Sterling, U.S. dollars or other currencies.  The maximum aggregate principal amount outstanding of ECP Notes at any time is $2,000.0. As of September 30, 2021, there were no ECP Notes outstanding.

Amounts available under the Commercial Paper Programs may be borrowed, repaid and re-borrowed from time to time. In conjunction with the Revolving Credit Facility, the authorization from the Company’s Board of Directors limits the maximum principal amount outstanding of USCP Notes, ECP Notes, and any other commercial paper or similar programs, along with outstanding amounts under the Revolving Credit Facility, at any time to $2,500.0 in the aggregate. The Commercial Paper Programs are rated A-2 by Standard & Poor’s and P-2 by Moody’s and are currently backstopped by the Revolving Credit Facility, as amounts undrawn under the Company’s Revolving Credit Facility are available to repay Commercial Paper, if necessary. Net proceeds of the issuances of Commercial Paper are expected to be used for general corporate purposes. The Commercial Paper is classified as long-term debt in the accompanying Condensed Consolidated Balance Sheets since the Company has the intent and ability to refinance the Commercial Paper on a long-term basis using the Company’s Revolving Credit Facility. The Commercial Paper is actively traded and is therefore classified as Level 1 in the fair value hierarchy (Note 5). The carrying value of Commercial Paper borrowings approximates their fair value.  

U.S. Senior Notes

On September 14, 2021, the Company issued $750.0 principal amount of unsecured 2.200% Senior Notes due September 15, 2031 at 99.634% of face value (the “2031 Senior Notes”). The 2031 Senior Notes are unsecured and rank equally in right of payment with the Company’s other unsecured senior indebtedness. Interest on the 2031 Senior Notes is payable semiannually on March 15 and September 15 of each year, commencing on March 15, 2022. Prior to June 15, 2031, the Company may, at its option, redeem some or all of the 2031 Senior Notes at any time by paying the redemption price (which may include a make-whole premium), plus accrued and unpaid interest, if any, to, but not including, the date of redemption. If redeemed on or after June 15, 2031, the Company may, at its option, redeem some or all of the 2031 Senior Notes at any time by paying the redemption price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including, the date of redemption. The Company used the net proceeds from the 2031 Senior Notes to repay certain outstanding borrowings under the U.S. Commercial Paper Program.

On February 20, 2020, the Company issued $400.0 principal amount of unsecured 2.050% Senior Notes due March 1, 2025 at 99.829% of face value (the “2025 Senior Notes”). The 2025 Senior Notes are unsecured and rank equally in right of payment with the Company’s other unsecured senior indebtedness. Interest on the 2025 Senior Notes is payable semiannually on March 1 and September 1 of each year, commencing on September 1, 2020.  Prior to February 1, 2025, the Company may, at its option, redeem some or all of the 2025 Senior Notes at any time by paying the redemption price (which may include a make-whole premium), plus accrued and unpaid interest, if any, to, but not including, the date of redemption. If redeemed on or after February 1, 2025, the Company may, at its option, redeem some or all of the 2025 Senior Notes at any time by paying the redemption price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including, the date of redemption.  On April 1, 2020, the Company used the net proceeds from the 2025 Senior Notes to repay the $400.0 principal amount of unsecured 2.20% Senior Notes due April 1, 2020 upon maturity.

All of the Company’s outstanding senior notes in the United States (the “U.S. Senior Notes”) are unsecured and rank equally in right of payment with the Company’s other unsecured senior indebtedness. Interest on each series of U.S. Senior Notes is payable semiannually. The Company may, at its option, redeem some or all of any series of U.S. Senior Notes at any time subject to certain terms and conditions, which include paying 100% of the principal amount, plus accrued and unpaid interest, if any, to the date of redemption, and, with certain exceptions, a make-whole premium. The fair value of each series of U.S. Senior Notes is based on recent bid prices in an active market and is therefore classified as Level 1 in the fair value hierarchy (Note 5). The remaining principal amount outstanding associated with

10

Table of Contents

the Company’s 4.00% Senior Notes (the “2022 Senior Notes”) due in February 2022 is recorded, net of the related unamortized discount and debt issuance costs, within Current portion of long-term debt in the accompanying Condensed Consolidated Balance Sheets as of September 30, 2021. On October 1, 2021, the Company issued a notice of full redemption to the holders of the 2022 Senior Notes, which will be redeemed at par value on November 1, 2021. The U.S. Senior Notes contain certain financial and non-financial covenants. At September 30, 2021, the Company was in compliance with the financial covenants under its U.S. Senior Notes.

Euro Senior Notes

On May 4, 2020, the Euro Issuer issued €500.0 (approximately $545.4 at date of issuance) principal amount of unsecured 0.750% Senior Notes due May 4, 2026 at 99.563% of face value (the “2026 Euro Notes” or the “0.750% Euro Senior Notes”, collectively with the 2.000% Euro Senior Notes due October 2028, the “Euro Notes”, and the Euro Notes collectively with the U.S. Senior Notes, the “Senior Notes”). The 2026 Euro Notes are unsecured and rank equally in right of payment with the Euro Issuer’s other unsecured senior indebtedness, and are fully and unconditionally guaranteed on a senior unsecured basis by the Company. Interest on the 2026 Euro Notes is payable annually on May 4 of each year, commencing on May 4, 2021. Prior to February 4, 2026, the Company may, at its option, redeem some or all of the 2026 Euro Notes at any time by paying the redemption price (which may include a make-whole premium), plus accrued and unpaid interest, if any, to, but not including, the date of redemption. If redeemed on or after February 4, 2026, the Company may, at its option, redeem some or all of the 2026 Euro Notes at any time by paying the redemption price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including, the date of redemption. The Company used the net proceeds from the 2026 Euro Notes to repay amounts outstanding under the Revolving Credit Facility.

The Company’s Euro Notes are unsecured and rank equally in right of payment with the Euro Issuer’s other unsecured senior indebtedness, and are fully and unconditionally guaranteed on a senior unsecured basis by the Company. Interest on each series of Euro Notes is payable annually. The Company may, at its option, redeem some or all of any series of Euro Notes at any time subject to certain terms and conditions, which include paying 100% of the principal amount, plus accrued and unpaid interest, if any, to, but not including, the date of redemption, and, with certain exceptions, a make-whole premium. The fair value of each series of Euro Notes is based on recent bid prices in an active market and is therefore classified as Level 1 in the fair value hierarchy (Note 5). The Euro Notes contain certain financial and non-financial covenants. At September 30, 2021, the Company was in compliance with the financial covenants under its Euro Notes.

Note 5—Fair Value Measurements

Fair value is determined based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. These requirements establish market or observable inputs as the preferred source of values. Assumptions based on hypothetical transactions are used in the absence of market inputs. The Company does not have any non-financial instruments accounted for at fair value on a recurring basis.

The valuation techniques required are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1           Quoted prices for identical instruments in active markets.

Level 2           Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3           Significant inputs to the valuation model are unobservable.

11

Table of Contents

The Company believes that the assets or liabilities currently subject to such standards with fair value disclosure requirements are primarily debt instruments, pension plan assets, short-term investments, and derivative instruments. Each of these assets and liabilities is discussed below, with the exception of debt instruments and pension plan assets, which are covered in Note 4 and Note 10, respectively, herein, in addition to the Notes to Consolidated Financial Statements in the 2020 Annual Report. Substantially all of the Company’s short-term investments consist of certificates of deposit with original maturities of twelve months or less and as such, are considered as Level 1 in the fair value hierarchy as they are traded in active markets for identical assets. The carrying amounts of these instruments, the majority of which are in non-U.S. bank accounts, approximate their fair value. The Company’s derivative instruments primarily consist of foreign exchange forward contracts, which are valued using bank quotations based on market observable inputs such as forward and spot rates and are therefore classified as Level 2 in the fair value hierarchy. The impact of the credit risk related to these financial assets is immaterial. The fair values of the Company’s financial and non-financial assets and liabilities subject to such standards as of September 30, 2021 and December 31, 2020 are as follows:

Fair Value Measurements

Quoted Prices in

Significant

Significant

Active Markets

Observable

Unobservable

for Identical

Inputs

Inputs

Total

Assets (Level 1)

(Level 2)

(Level 3)

September 30, 2021:

Short-term investments

$

34.4

$

34.4

$

$

Forward contracts

(5.4)

(5.4)

Total

$

29.0

$

34.4

$

(5.4)

$

December 31, 2020:

Short-term investments

$

36.1

$

36.1

$

$

Forward contracts

(2.7)

(2.7)

Total

$

33.4

$

36.1

$

(2.7)

$

As of September 30, 2021, the fair value of such forward contracts in the table above consisted of (i) two outstanding foreign exchange forward contracts accounted for as cash flow hedges, with each expiring within one year, (ii) various outstanding foreign exchange forward contracts accounted for as net investment hedges and (iii) various outstanding foreign exchange forward contracts that are not designated as hedging instruments. The amounts recognized in Accumulated other comprehensive income (loss) associated with foreign exchange forward contracts and the amounts reclassified from Accumulated other comprehensive income (loss) to foreign exchange gain (loss), included in Cost of sales in the accompanying Condensed Consolidated Statements of Income during the three and nine months ended September 30, 2021 and 2020, were not material. The fair values of the Company’s forward contracts are recorded within Prepaid expenses and other current assets, Other long-term assets, Other accrued expenses and Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets, depending on their value and remaining contractual period.

As further discussed in Note 12 herein, the MTS T&S business met the held for sale criteria upon the acquisition of MTS on April 7, 2021. As a result, the disposal group was measured at fair value less costs to sell, which is considered a Level 3 fair value measurement based on the transaction’s expected consideration. The Company reassessed the fair value of these assets held for sale and liabilities held for sale as of September 30, 2021 and noted that the carrying value of the disposal group did not exceed its fair value less costs to sell.

With the exception of the fair value of the assets acquired and liabilities assumed in connection with acquisition accounting as well as the assets held for sale and liabilities held for sale discussed above, the Company does not have any other significant financial or non-financial assets and liabilities that are measured at fair value on a non-recurring basis.

12

Table of Contents

Note 6—Income Taxes

Three Months Ended

Nine Months Ended

    

September 30, 

    

September 30, 

2021

2020

2021

2020

Provision for income taxes

$

(120.5)

$

(99.3)

$

(302.8)

$

(213.3)

Effective tax rate

 

22.2

%  

 

22.1

%  

 

21.2

%  

 

20.0

%

For the three months ended September 30, 2021 and 2020, stock option exercise activity had the impact of decreasing our Provision for income taxes by $12.3 and $10.7, respectively, and decreasing our effective tax rate by 230 basis points and 240 basis points, respectively, due to the recognition of excess tax benefits within Provision for income taxes in the accompanying Condensed Consolidated Statements of Income. For the nine months ended September 30, 2021 and 2020, stock option exercise activity had the impact of decreasing our Provision for income taxes by $34.3 and $28.1, respectively, and decreasing our effective tax rate by 240 basis points and 260 basis points, respectively. For the nine months ended September 30, 2021, the effective tax rate includes a discrete tax benefit of $14.9 related to the settlement of uncertain tax positions in certain non-U.S. jurisdictions, which had the effect of decreasing the effective tax rate by 100 basis points, as well as the impact of acquisition-related expenses, which had the effect of increasing the effective tax rate by approximately 20 basis points. For the nine months ended September 30, 2020, the effective tax rate also included a discrete tax benefit related to the settlements of refund claims in a non-U.S. jurisdiction and the resulting adjustments to deferred taxes, which had the impact of decreasing our Provision for income taxes and effective tax rate by $19.9 and 190 basis points, respectively.

On December 22, 2017, the United States federal government enacted the Tax Cuts and Jobs Act (“Tax Act”), marking a change from a worldwide tax system to a modified territorial tax system in the United States. As part of this change, the Tax Act, among other changes, provides for a transition tax (“Transition Tax”) related to the deemed repatriation of the accumulated unremitted earnings and profits of the Company’s foreign subsidiaries. The Company paid its fourth annual installment of the Transition Tax, net of applicable tax credits and deductions, in the second quarter of 2021, and will pay the balance of the Transition Tax, net of applicable tax credits and deductions, over the remainder of the eight-year period ending 2025, as permitted under the Tax Act. The current and long-term portions of the Transition Tax are recorded in Accrued income taxes and Other long-term liabilities, respectively, on the Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020.

The Company operates in the U.S. and numerous foreign taxable jurisdictions, and at any point in time has numerous audits underway at various stages of completion. With few exceptions, the Company is subject to income tax examinations by tax authorities for the years 2017 and after. The Company is generally not able to precisely estimate the ultimate settlement amounts or timing until the close of an audit. The Company evaluates its tax positions and establishes liabilities for uncertain tax positions that may be challenged by tax authorities and may not be fully sustained, despite the Company’s belief that the underlying tax positions are fully supportable. As of September 30, 2021, the amount of unrecognized tax benefits, including penalties and interest, which if recognized would impact the effective tax rate, was approximately $157.0. Unrecognized tax benefits are reviewed on an ongoing basis and are adjusted for changing facts and circumstances, including the progress of tax audits and the closing of statutes of limitations. Based on information currently available, management anticipates that over the next twelve-month period, audit activity could be completed and statutes of limitations may close relating to existing unrecognized tax benefits of approximately $6.8.

Note 7—Shareholders’ Equity and Noncontrolling Interests

Net income from continuing operations attributable to noncontrolling interests is classified below net income from continuing operations. Earnings per share is determined after the impact of the noncontrolling interests’ share in net income of the Company. In addition, the equity attributable to noncontrolling interests is presented as a separate caption within equity.

13

Table of Contents

A rollforward of consolidated changes in equity for the three months ended September 30, 2021 is as follows:

Amphenol Corporation Shareholders

Accumulated

Common Stock

Treasury Stock

Other

    

Shares

Shares

Additional

Retained

Comprehensive

Noncontrolling

Total

(in millions)

    

Amount

    

(in millions)

    

Amount

    

Paid-In Capital

    

Earnings

    

Loss

    

Interests

    

Equity

 

Balance as of June 30, 2021

599.3

 

$

0.6

 

(1.8)

 

$

(100.1)

 

$

2,198.9

 

$

3,916.4

 

$

(300.3)

 

$

62.8

 

$

5,778.3

Net income

 

426.5

 

2.9

 

429.4

Other comprehensive income (loss)

 

(35.2)

 

0.1

 

(35.1)

Distributions to shareholders of noncontrolling interests

 

(3.0)

 

(3.0)

Purchase of treasury stock

(2.3)

 

(170.9)

 

(170.9)

Retirement of treasury stock

 

(2.3)

2.3

 

170.9

 

(170.9)

 

Stock options exercised

 

2.2

0.2

10.8

 

69.4

(4.7)

 

75.5

Dividends declared ($0.145 per common share)

 

(86.7)

 

(86.7)

Stock-based compensation expense

 

21.2

 

21.2

Balance as of September 30, 2021

 

599.2

$

0.6

(1.6)

$

(89.3)

$

2,289.5

$

4,080.6

$

(335.5)

$

62.8

$

6,008.7

A rollforward of consolidated changes in equity for the nine months ended September 30, 2021 is as follows:

Amphenol Corporation Shareholders

Accumulated

Common Stock

Treasury Stock

Other

Shares

Shares

Additional

Retained

Comprehensive

Noncontrolling

Total

    

(in millions)

    

Amount

    

(in millions)

    

Amount

    

Paid-In Capital

    

Earnings

    

Loss

    

Interests

    

Equity

Balance as of December 31, 2020

 

600.7

 

$

0.6

 

(2.0)

 

$

(111.1)

 

$

2,068.1

 

$

3,705.4

 

$

(278.1)

 

$

67.0

 

$

5,451.9

Net income

 

1,125.8

 

6.9

 

1,132.7

Other comprehensive income (loss)

 

(57.4)

 

0.9

 

(56.5)

Acquisitions resulting in noncontrolling interest

 

1.8

 

1.8

Purchase of noncontrolling interest

2.5

(7.3)

(4.8)

Distributions to shareholders of noncontrolling interests

 

(6.5)

 

(6.5)

Purchase of treasury stock

(7.2)

 

(491.0)

 

(491.0)

Retirement of treasury stock

 

(6.9)

6.9

 

471.2

 

(471.2)

 

Stock options exercised

 

5.4

0.7

41.6

 

158.7

(19.5)

 

180.8

Dividends declared ($0.435 per common share)

 

(259.9)

 

(259.9)

Stock-based compensation expense

 

60.2

 

60.2

Balance as of September 30, 2021

 

599.2

 

$

0.6

 

(1.6)

 

$

(89.3)

 

$

2,289.5

 

$

4,080.6

 

$

(335.5)

 

$

62.8

 

$

6,008.7

A rollforward of consolidated changes in equity for the three months ended September 30, 2020 is as follows:

Amphenol Corporation Shareholders

Accumulated

Common Stock

Treasury Stock

Other

 

Shares

Shares

Additional

Retained

Comprehensive

Noncontrolling

Total

 

(in millions)

    

Amount

    

(in millions)

    

Amount

    

Paid-In Capital

    

Earnings

    

Loss

    

Interests

    

Equity

Balance as of June 30, 2020

597.1

 

$

0.6

 

(0.5)

 

$

(21.0)

 

$

1,834.2

 

$

3,419.4

 

$

(494.6)

 

$

61.7

 

$

4,800.3

Net income

 

346.6

 

2.9

 

349.5

Other comprehensive income (loss)

 

106.2

 

2.3

 

108.5

Distributions to shareholders of noncontrolling interests

 

(1.9)

 

(1.9)

Purchase of treasury stock

(3.7)

 

(201.9)

 

(201.9)

Retirement of treasury stock

 

(1.7)

1.7

 

91.6

 

(91.6)

 

Stock options exercised

 

3.3

0.7

34.4

 

84.6

(12.6)

 

106.4

Dividends declared ($0.125 per common share)

 

 

(74.7)

 

(74.7)

Stock-based compensation expense

 

19.0

 

19.0

Balance as of September 30, 2020

598.7

$

0.6

(1.8)

$

(96.9)

$

1,937.8

$

3,587.1

$

(388.4)

$

65.0

$

5,105.2

14

Table of Contents

A rollforward of consolidated changes in equity for the nine months ended September 30, 2020 is as follows:

Amphenol Corporation Shareholders

Accumulated

Common Stock

Treasury Stock

Other

Shares

Shares

Additional

Retained

Comprehensive

Noncontrolling

Total

    

(in millions)

    

Amount

    

(in millions)

    

Amount

    

Paid-In Capital

    

Earnings

    

Loss

    

Interests

    

Equity

Balance as of December 31, 2019

 

597.4

 

$

0.6

 

(1.6)

 

$

(70.8)

 

$

1,683.0

 

$

3,348.4

 

$

(430.9)

 

$

65.9

 

$

4,596.2

Cumulative effect of adoption of credit loss standard (ASU 2016-13)

(3.8)

(3.8)

Net income

 

846.4

 

6.7

 

853.1

Other comprehensive income (loss)

 

42.5

1.5

 

44.0

Acquisitions resulting in noncontrolling interest

 

0.3

 

0.3

Purchase of noncontrolling interest

(2.1)

(5.2)

(7.3)

Distributions to shareholders of noncontrolling interests

 

(4.2)

 

(4.2)

Purchase of treasury stock

(9.1)

 

(459.2)

 

(459.2)

Retirement of treasury stock

 

(7.1)

7.1

 

348.9

 

(348.9)

 

Stock options exercised

 

8.4

1.8

84.2

 

205.9

(31.8)

 

258.3

Dividends declared ($0.375 per common share)

 

(223.2)

 

(223.2)

Stock-based compensation expense

 

 

51.0

 

 

 

 

 

51.0

Balance as of September 30, 2020

 

598.7

 

$

0.6

 

(1.8)

 

$

(96.9)

 

$

1,937.8

 

$

3,587.1

 

$

(388.4)

 

$

65.0

 

$

5,105.2

Authorized Shares for Issuance

On May 19, 2021, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation, which increased the total number of shares of Class A Common Stock, $0.001 par value (“Common Stock”) that the Company is authorized to issue to 2,000,000,000 shares, an increase of 1,000,000,000 shares from the amount previously authorized. The amendment was filed and became effective on May 21, 2021.

Stock Repurchase Programs

On April 24, 2018, the Company’s Board of Directors authorized a stock repurchase program under which the Company could purchase up to $2,000.0 of the Company’s Common Stock during the three-year period ending April 24, 2021 (the “2018 Stock Repurchase Program”) in accordance with the requirements of Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). During the first nine months of 2021, the Company repurchased 3.1 million shares of its Common Stock for $203.8 under the 2018 Stock Repurchase Program. As a result of these purchases, the Company completed all purchases authorized under the 2018 Stock Repurchase Program and, therefore, the 2018 Stock Repurchase Program has terminated. Of the total repurchases made during the first nine months of 2021, 0.3 million shares, or $19.8, were retained in Treasury stock at the time of repurchase; the remaining 2.8 million shares, or $184.0, were retired by the Company. During the three and nine months ended September 30, 2020, the Company repurchased 3.7 million and 9.1 million shares of its Common Stock for $201.9 and $459.2, respectively, under the 2018 Stock Repurchase Program. Of the total repurchases made during the first nine months of 2020, 2.0 million shares, or $110.3, were retained in Treasury stock at the time of repurchase; the remaining 7.1 million shares, or $348.9, were retired by the Company.

On April 27, 2021, the Company’s Board of Directors authorized a new stock repurchase program under which the Company may purchase up to $2,000.0 of the Company’s Common Stock during the three-year period ending April 27, 2024 (the “2021 Stock Repurchase Program”) in accordance with the requirements of Rule 10b-18 of the Exchange Act. During the three and nine months ended September 30, 2021, the Company repurchased 2.3 million and 4.1 million shares of its Common Stock for $170.9 and $287.2, respectively, under the 2021 Stock Repurchase Program. All of the shares repurchased under the 2021 Stock Repurchase Program during the nine months ended September 30, 2021 have been or will be retired by the Company. From October 1, 2021 to October 26, 2021, the Company repurchased 0.6 million additional shares of its Common Stock for $46.1 under the 2021 Stock Repurchase Program, and has remaining authorization to purchase up to $1,666.6 of its Common Stock under the 2021 Stock Repurchase Program. The price and timing of any future purchases under the 2021 Stock Repurchase Program will depend on a number of factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends paid, economic and market conditions and the price of the Company’s Common Stock.

15

Table of Contents

Dividends

Contingent upon declaration by the Company’s Board of Directors, the Company pays a quarterly dividend on shares of its Common Stock. The following table summarizes the dividends declared and paid for the three and nine months ended September 30, 2021 and 2020:

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2021

2020

2021

2020

Dividends declared

$

86.7

$

74.7

$

259.9

$

223.2

Dividends paid (including those declared in the prior year)

 

86.6

 

74.6

 

260.0

 

223.0

On October 20, 2020, the Company’s Board of Directors approved an increase to its quarterly dividend rate from $0.125 per share to $0.145 per share effective with dividends declared in the fourth quarter of 2020, and then on October 26, 2021, approved a further increase to its quarterly dividend rate from $0.145 per share to $0.20 per share effective with dividends declared in the fourth quarter of 2021, contingent upon declaration by the Company’s Board of Directors.

Note 8—Stock-Based Compensation

For the three months ended September 30, 2021 and 2020, the Company’s Income from continuing operations before income taxes was reduced for stock-based compensation expense of $21.2 and $19.0, respectively. In addition, for the three months ended September 30, 2021 and 2020, the Company recognized aggregate income tax benefits of $14.0 and $12.7, respectively, in Provision for income taxes in the accompanying Condensed Consolidated Statements of Income associated with stock-based compensation. These aggregate income tax benefits during the three months ended September 30, 2021 and 2020 include excess tax benefits of $12.3 and $10.7, respectively, from option exercises.

For the nine months ended September 30, 2021 and 2020, the Company’s Income from continuing operations before income taxes was reduced for stock-based compensation expense of $60.2 and $51.0, respectively. In addition, for the nine months ended September 30, 2021 and 2020, the Company recognized aggregate income tax benefits of $40.4 and $33.8, respectively, in Provision for income taxes in the accompanying Condensed Consolidated Statements of Income associated with stock-based compensation. These aggregate income tax benefits during the nine months ended September 30, 2021 and 2020 include excess tax benefits of $34.3 and $28.1, respectively, from option exercises.

The impact associated with recognizing excess tax benefits from option exercises in the provision for income taxes on our consolidated financial statements could result in significant fluctuations in our effective tax rate in the future, since the provision for income taxes will be impacted by the timing and intrinsic value of future stock-based compensation award exercises.

Stock-based compensation expense includes the estimated effects of forfeitures, which are adjusted over the requisite service period to the extent actual forfeitures differ or are expected to differ from such estimates. Changes in estimated forfeitures are recognized in the period of change and impact the amount of expense to be recognized in future periods. The expense incurred for stock-based compensation plans is included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Income.

Stock Options

In May 2017, the Company adopted the 2017 Stock Purchase and Option Plan for Key Employees of Amphenol and Subsidiaries (the “2017 Employee Option Plan”), which provided for the issuance of 60,000,000 shares.  In March 2021, the Company’s Board of Directors authorized and approved the Amended and Restated 2017 Stock Purchase and Option Plan for Key Employees of Amphenol and Subsidiaries (the “Amended 2017 Employee Option Plan” and, together with the 2017 Employee Option Plan, the “2017 Option Plan”), which among other things, increased the number of shares reserved for issuance under the plan by 40,000,000 shares. The Amended 2017 Employee Option Plan was approved by the Company’s shareholders and became effective on May 19, 2021. As of September 30, 2021, there were 43,038,110 shares of Common Stock available for the granting of additional stock options under the Amended 2017 Employee

16

Table of Contents

Option Plan. Prior to the approval of the 2017 Employee Option Plan, the Company issued stock options under the 2009 Stock Purchase and Option Plan for Key Employees of Amphenol and Subsidiaries, and its amendment (the “2009 Employee Option Plan”). No additional stock options will be granted under the 2009 Employee Option Plan.  Options granted under the 2017 Option Plan and the 2009 Employee Option Plan generally vest ratably over a period of five years from the date of grant and are generally exercisable over a period of ten years from the date of grant.  

Stock option activity for the three and nine months ended September 30, 2021 was as follows:

Weighted

 

Average

Aggregate

 

Weighted

Remaining

Intrinsic

 

Average

Contractual

Value

    

Options

    

Exercise Price

    

Term (in years)

    

(in millions)

 

Options outstanding at January 1, 2021

 

67,985,648

$

37.58

 

6.79

$

1,890.4

Options granted

 

215,080

 

64.69

Options exercised

 

(757,598)

 

28.12

Options forfeited

 

(31,160)

 

42.37

Options outstanding at March 31, 2021

 

67,411,970

37.77

6.57

1,901.0

Options granted

 

7,215,100

 

66.62

Options exercised

 

(2,882,332)

 

29.14

Options forfeited

 

(46,600)

 

49.05

Options outstanding at June 30, 2021

 

71,698,138

41.01

 

6.77

1,964.3

Options granted

 

95,400

 

71.64

Options exercised

 

(2,494,842)

 

30.30

Options forfeited

 

(200,890)

 

48.28

Options outstanding at September 30, 2021

 

69,097,806

$

41.42

 

6.60

$

2,198.0

Vested and non-vested options expected to vest at September 30, 2021

 

65,684,351

$

41.03

 

6.52

$

2,114.9

Exercisable options at September 30, 2021

 

37,432,076

$

34.81

 

5.33

$

1,438.1

A summary of the status of the Company’s non-vested options as of September 30, 2021 and changes during the three and nine months then ended is as follows:

    

    

Weighted

 

Average

Fair Value at 

Options

Grant Date

 

Non-vested options at January 1, 2021

 

36,989,300

$

6.43

Options granted

 

215,080

 

12.11

Options vested

 

(91,200)

 

3.88

Options forfeited

 

(31,160)

 

5.77

Non-vested options at March 31, 2021

 

37,082,020

6.46

Options granted

 

7,215,100

 

13.29

Options vested

 

(12,345,300)

 

5.70

Options forfeited

 

(46,600)

 

7.97

Non-vested options at June 30, 2021

 

31,905,220

8.30

Options granted

 

95,400

 

14.19

Options vested

 

(134,000)

 

4.76

Options forfeited

 

(200,890)

 

8.09

Non-vested options at September 30, 2021

 

31,665,730

$

8.33

17

Table of Contents

During the three and nine months ended September 30, 2021 and 2020, the following activity occurred under the Company’s option plans:

 

Three Months Ended

    

Nine Months Ended

 

September 30, 

September 30, 

2021

2020

2021

2020

Total intrinsic value of stock options exercised

$

108.1

$

107.6

$

246.5

$

277.9

Total fair value of stock options vested

 

0.6

 

0.8

 

71.4

 

62.1

As of September 30, 2021, the total compensation cost related to non-vested options not yet recognized was approximately $216.1 with a weighted average expected amortization period of 3.54 years.

The grant-date fair value of each option grant under the 2009 Employee Option Plan and the 2017 Option Plan is estimated using the Black-Scholes option pricing model. The grant-date fair value of each share grant is determined based on the closing share price of the Company’s Common Stock on the date of the grant. The fair value is then amortized on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Use of a valuation model for option grants requires management to make certain assumptions with respect to selected model inputs. Expected share price volatility is calculated based on the historical volatility of the Common Stock and implied volatility derived from related exchange traded options. The average expected life is based on the contractual term of the option and expected exercise and historical experience. The risk-free interest rate is based on U.S. Treasury zero-coupon issuances with a remaining term equal to the expected life assumed at the date of grant. The expected annual dividend per share is based on the Company’s dividend rate.

Restricted Shares

In 2012, the Company adopted the 2012 Restricted Stock Plan for Directors of Amphenol Corporation (the “2012 Directors Restricted Stock Plan”). The 2012 Directors Restricted Stock Plan is administered by the Company’s Board of Directors. As of September 30, 2021, the number of restricted shares available for grant under the 2012 Directors Restricted Stock Plan was 141,359. Restricted shares granted under the 2012 Directors Restricted Stock Plan generally vest on the first anniversary of the grant date. Grants under the 2012 Directors Restricted Stock Plan entitle the holder to receive shares of the Company’s Common Stock without payment.

Restricted share activity for the three and nine months ended September 30, 2021 was as follows:

Weighted Average

Remaining

Restricted

Fair Value at 

Amortization

  

Shares

 

Grant Date

 

Term (in years)

 

Restricted shares outstanding at January 1, 2021

 

26,350

$

45.55

0.38

Restricted shares granted

 

 

Restricted shares outstanding at March 31, 2021

 

26,350

45.55

 

0.13

Shares vested and issued

 

(27,272)

 

45.80

Restricted shares granted

 

20,146

 

65.96

Restricted shares outstanding at June 30, 2021

 

19,224

66.59

 

0.88

Restricted shares granted

 

1,837

 

70.39

Restricted shares outstanding at September 30, 2021

  

21,061

 

$

66.92

 

0.62

As of September 30, 2021, the total compensation cost related to non-vested restricted shares not yet recognized was approximately $0.9 (with a weighted average expected amortization period of 0.62 years).

Note 9—Earnings Per Share

Basic earnings per share (“EPS”) is computed by dividing net income attributable to Amphenol Corporation by the weighted average number of common shares outstanding. Diluted EPS is computed by dividing net income attributable to Amphenol Corporation by the weighted average number of outstanding common shares, including dilutive common

18

Table of Contents

shares, the dilutive effect of which relates to stock options. A reconciliation of the basic weighted average common shares outstanding to diluted weighted average common shares outstanding, along with the earnings per share (basic and diluted) for the three and nine months ended September 30, 2021 and 2020 is as follows (note - per share amounts may not add due to rounding):

Three Months Ended September 30, 

Nine Months Ended September 30, 

(dollars and shares in millions, except per share data)

    

2021

   

2020

    

2021

   

2020

 

Net income attributable to Amphenol Corporation shareholders:

Net income from continuing operations attributable to Amphenol Corporation

$

418.8

$

346.6

$

1,115.5

$

846.4

Income from discontinued operations attributable to Amphenol Corporation, net of income taxes of ($1.5) and ($1.8) for 2021, respectively

7.7

10.3

Net income attributable to Amphenol Corporation

$

426.5

$

346.6

$

1,125.8

$

846.4